Neurocrine Biosciences (NBIX) Announces Earnings Results, Misses Expectations By $0.11 EPS
Neurocrine Biosciences (NASDAQ:NBIX) announced its earnings results on Tuesday. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.11), Bloomberg Earnings reports. During the same quarter last year, the business earned ($0.51) earnings per share.
Neurocrine Biosciences (NBIX) opened at $83.69 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37. The firm has a market capitalization of $7,271.47, a P/E ratio of -37.70, a price-to-earnings-growth ratio of 6.41 and a beta of 0.26. Neurocrine Biosciences has a one year low of $39.21 and a one year high of $91.82.
In other news, insider Darin Lippoldt sold 6,279 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $75.04, for a total transaction of $471,176.16. Following the completion of the transaction, the insider now directly owns 19,436 shares in the company, valued at approximately $1,458,477.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dimitri E. Grigoriadis sold 86,368 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $78.32, for a total value of $6,764,341.76. Following the transaction, the insider now owns 154,717 shares of the company’s stock, valued at $12,117,435.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 337,950 shares of company stock valued at $26,613,876. Corporate insiders own 4.80% of the company’s stock.
A number of equities research analysts recently issued reports on NBIX shares. Jefferies Group lifted their target price on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets lifted their target price on Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Oppenheimer set a $85.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, December 12th. Needham & Company LLC reissued a “buy” rating and issued a $86.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Leerink Swann reissued an “outperform” rating and issued a $83.00 target price (up previously from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $88.33.
WARNING: “Neurocrine Biosciences (NBIX) Announces Earnings Results, Misses Expectations By $0.11 EPS” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://theolympiareport.com/2018/02/14/neurocrine-biosciences-nbix-announces-earnings-results-misses-expectations-by-0-11-eps.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.